IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 8546 
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded240    
    Comments [Add]    

Recommend this journal


Year : 1992  |  Volume : 24  |  Issue : 3  |  Page : 147-153

Reversal of scopolamine- and dizocilpine- induced memory dysfunction by angiotensin converting enzyme inhibitors in rats and mice

Correspondence Address:
A C Sharma

Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

Cholinergic muscarinic antagonists, atropine (1-5 mg/kg) and scopolamine (0.1-0.5 mg/kg) produced learning and memory deficits in step-down passive avoidance task paradigm in mice. NMDA-receptor antagonist (noncompetitive), MK 801 (0.1 mgikg) produced complete disruption of acquisition and retention, however, lower doses (0.025-0.05 mg/kg) showed improvement in retention parameters. Scopolamine potentiated memory disruptive effects of MK 801 (0.05 mg/kg). Combined administration of MK 801 (0.01 mg/kg) and scopolamine (0.3 mg/kg) - induced deficits were not reversed by physostigmine in step-down passive avoidance paradigm. Piracetam and aniracetam decreased number of mistakeson step-down task in scopolamine -treated and-untreated mice. These agents also showed reduction in shortened transfer latency (TL) on elevated plus-maze apparatus. The effect was reversed by MK 801 and scopolamine, both in rats and mice. Captopril (30 mg/kg) and enalapril (30 and 60 mgikg) attenuated scopolamine- induced deficits on step-down task paradigm, but not on elevated plus maze in rats and mice. The effects were being comparable to piracetam. However, captopril at lower doses (5-15 mgikg) did not show impairment of latency in reaching shock free zone (SFZ), unlike enalapril and prove to be more potent than enalapril on both paradigms. The results suggested a unidirectional pattern of activity of NMDA- and cholinergic- antagonism in the bahavioural expression of amnesia. Captopril was found to be more potent than enalapril in improving retention or consolidation phase of memory, the effect com-parable to nootropics, and proposed to involve central cholinergic and NMDA receptor modulation.


Print this article     Email this article

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer | Privacy Notice
Online since 20th July '04
Published by Wolters Kluwer - Medknow